Bringing Clarity to Clinical Decisions
Early detection remains essential to improving outcomes for bladder cancer patients.
Management Team
Our management team comprises seasoned professionals dedicated to driving our company toward excellence and innovation. With a diverse range of expertise and a shared commitment to our mission, each member plays a pivotal role in shaping the strategic direction and ensuring the sustainable growth of our organization.
Explore our team profiles to learn more about their backgrounds, experiences, and unique strengths. Together, they embody the vision and values that propel us forward, fostering a culture of integrity, collaboration, and patient-centricity.
Christopher Thibodeau
Chief Executive Officer
Christopher is an established leader in molecular diagnostics for urology and oncology. He has led team initiatives that successfully established operations, launched innovative products, delivered clinical validation, gained guideline inclusion, secured reimbursement, and generated clinical adoption.
Laura Caba, MPH
President
With a track record of leadership in the fields of urology and oncology, Laura is leveraging her experience to redefine the early detection of bladder cancer. With a deep understanding of the clinical landscape, Laura is dedicated to fostering innovation and delivering on the promise of improving patient care and clinical outcomes.
WIll Lowrance, MD, MPH, MBA
Chief Medical Officer
As a former professor (Huntsman Cancer Institute) and fellowship-trained urologic oncologist (Vanderbilt, MSKCC, Harvard), Dr. Lowrance has led clinical trials in bladder cancer and helped shape clinical guidelines. His current practice and research efforts focus on improving clinical care and outcomes for patients. Dr. Lowrance has published numerous peer-reviewed urologic articles, book chapters, and editorials.
Manuel Krispin, PhD
Chief Scientific Officer
With a PhD in Epigenetics, Dr. Krispin has successfully developed and validated numerous molecular diagnostic assays, particularly in DNA-methylation analysis, genotyping, NGS assays, and multiplex PCR. Dr. Krispin was pivotal in the design of Vesica's AssureMDx test.
Scientific Advisory Board
Our Scientific Advisory Board comprises a renowned group of world-leading bladder cancer experts who bring unparalleled scientific knowledge and clinical perspectives to guide our research and development initiatives.
Explore the profiles of our Advisory Board members to learn more about their backgrounds and the clinical expertise they contribute. Together, they provide critical guidance and strategic insights, ensuring we stay at the forefront of scientific advancements and maintain our commitment to excellence in patient care.
Peter Black, MD, FACS
Professor and Vice Chair, Department of Urologic Sciences, Khosrowshahi Family Chair, University of British Columbia Senior Research Scientist, Vancouver Prostate Centre, Associate Director of Clinical Research, Vancouver Prostate Centre Urologic Oncologist, Vancouver General Hospital
Medical School: Johannes Gutenberg University in Mainz, Germany; Fellowship: Urologic Oncology, MD Anderson Cancer Center; Residency: Urology, University of Washington, Seattle
Yair Lotan, MD
Professor of Urology, Chief of Urologic Oncology, Jane and John Justin Distinguished Chair in Urology, in Honor of Claus G. Roehrborn, M.D. at the University of Texas Southwestern Medical Center, Vice-Chair of Clinical Affairs in the Department of Urology, Head of the Clinical Research Office and Medical Director of the Urology Clinic at UT Southwestern and Parkland Health and Hospital System
Medical School: Baylor College of Medicine; Residency: Surgery & Urology, University of Texas, Southwestern
Sam S. Chang, MD, MBA
Professor, Department of Urology, Patricia and Rodes Hart Chair of Urologic Surgery, Chief Surgical Officer, Vanderbilt Ingram Cancer Center, Chief, Division of Urologic Oncology, Vanderbilt University School of Medicine
Medical School: Vanderbilt University School of Medicine; Master of Business Administration: Owen School of Business, at Vanderbilt; Fellowship: Urologic Oncology, Memorial Sloan-Kettering Cancer Center; Residency: Urology & Surgery, Vanderbilt University Medical Center
Sima P. Porten, MD, MPH
Associate Professor of Urology, University of California, San Francisco, Urologic Oncology, Helen Diller Family Comprehensive Cancer Center Program Director, Urologic Oncology Fellowship Program (UCSF)
Medical School: Northwestern University, Feinberg School of Medicine; Master Public Health: Northwestern University, Feinberg School of Medicine; Fellowship: Urologic Oncology, Univ of Texas, MD Anderson Cancer Center; Residency: Surgery & Urology, University of California, San Francisco
Siamak Daneshmand, MD
Professor of Clinical Urology, Clinical Scholar, Director of Urologic Oncology, USC Institute of Urology, Urologic Oncology (SUO) Fellowship Director, Keck School of Medicine of the University of Southern California
Medical School: University of California, Davis; Fellowship: Urologic Oncology, USC Norris Comprehensive Cancer Center; Residency: University of Southern California
Cheryl T. Lee, MD
Professor, Chair of Urology, Dorothy M. Davis Chair in Cancer Research, Department of Urology, Wexner Medical Center, Ohio State University
Medical School: Albany Medical College; Fellowship: Urologic Oncology, Memorial Sloan-Kettering Cancer Center; Fellowship: Urology, University of Michigan Hospitals; Internship: Surgery, University of Michigan Hospitals; Residency: Urology, University of Michigan Hospitals; Residency: Surgery, University of North Carolina Healthcare
Board of Directors
Our Board comprises distinguished leaders with extensive experience and a deep commitment to our mission and values. Each member brings a wealth of knowledge and strategic insight, guiding our organization with integrity and foresight.
Explore the profiles of our Board members to learn more about their backgrounds and the expertise they contribute. Together, they provide strong governance and visionary leadership, ensuring our continued growth and success.
